Table 2.
Antimicrobial resistance prevalence and genetic determinants of resistance in groups A and B.
| Resistant phenotype | Group A % (n/N) | Group B % (n/N) | Total % (n/N) | AMR genetic determinants *(n isolates) | Main RT associated (n isolates) |
|---|---|---|---|---|---|
| Clindamycin | 25.5% (24/94) | 34.3% (12/35) | 27.9% (36/129) | ermB (36) | RT010 (23) |
| Moxifloxacin | 13.8% (13/94) | 8.6% (3/35) | 12.4% (16/129) | gyrA Thr82Ile (16) | RT106 (8) |
| Metronidazole | 12.8% (12/94) | 28.6% (10/35) | 17.1% (22/129) | pCD-METRO plasmid (22) | RT010 (22) |
| Rifampicin | 2.1% (2/94) | - | 2.1% (2/94) | rpoB Arg505Lys (1) rpoB His502Asn and Arg505Lys (1) | N.A. |
*Determined by PCR and/or Sanger sequencing. The gyrA mutation in RT106 isolates was confirmed by WGS.
N.A. there was no main associated RT.